Graded Cardiac Response Criteria For Patients With Systemic Light Chain Amyloidosis

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Eli Muchtar

Honoraria: Janssen

Consulting or Advisory Role: Protego Biopharma (Inst)

Angela Dispenzieri

Consulting or Advisory Role: Janssen Research & Development

Research Funding: Celgene (Inst), Janssen Oncology (Inst), Pfizer (Inst), Takeda (Inst), Alnylam (Inst), Prothena

Travel, Accommodations, Expenses: Pfizer, Janssen Oncology, Prothena

Giovanni Palladini

Honoraria: Janssen-Cilag, Siemens Healthcare Diagnostics, Alexion Pharmaceuticals, Protego Biopharma, The Binding Site, Pfizer, Prothena, Sebia

Consulting or Advisory Role: Janssen-Cilag, Alexion Pharmaceuticals, Protego Biopharma

Research Funding: The Binding Site (Inst)

Paolo Milani

Honoraria: Pfizer, Janssen-Cilag

Travel, Accommodations, Expenses: Celgene

Stefan Schönland

Honoraria: Janssen (Inst), Pfizer (Inst)

Consulting or Advisory Role: Janssen (Inst), Prothena (Inst)

Research Funding: Janssen-Cilag (Inst), Sanofi (Inst), Prothena (Inst), Medac

Travel, Accommodations, Expenses: Janssen-Cilag, Prothena, Sanofi

Ute Hegenbart

Honoraria: Janssen (Inst), Pfizer (Inst), Akcea Therapeutics (Inst), Alnylam (Inst)

Consulting or Advisory Role: Pfizer (Inst), Prothena (Inst), Janssen (Inst)

Research Funding: Janssen (Inst)

Travel, Accommodations, Expenses: Janssen (Inst), Prothena (Inst), Pfizer (Inst)

Susan M. Geyer

Research Funding: Brisol Myers Squibb (Inst), Johnson & Johnson/Janssen (Inst), Celgene (Inst)

Shaji K. Kumar

Honoraria: BeiGene, GLH Pharma, Secura Bio

Consulting or Advisory Role: Takeda (Inst), Janssen Oncology (Inst), Amgen (Inst), AbbVie (Inst), Celgene (Inst), Genentech/Roche (Inst), Oncopeptides, Kite, a Gilead Company (Inst), Genecentrix, Molecular Partners (Inst), Bluebird Bio (Inst)

Research Funding: Celgene (Inst), Takeda (Inst), AbbVie (Inst), Novartis (Inst), Sanofi (Inst), Janssen Oncology (Inst), Merck (Inst), Kite, a Gilead Company (Inst), MedImmune (Inst), Roche/Genentech (Inst), TeneoBio (Inst), CARsgen Therapeutics (Inst)

Efstathios Kastritis

Honoraria: Amgen, Genesis Pharma, Janssen Oncology, Takeda, Prothena, Pfizer, GlaxoSmithKline

Consulting or Advisory Role: Amgen, Janssen Oncology, Takeda, Genesis Pharma, Prothena, Pfizer

Research Funding: Janssen Oncology (Inst), Amgen (Inst)

Travel, Accommodations, Expenses: Janssen Oncology, Genesis Pharma, Takeda, Pfizer

Meletios A. Dimopoulos

Honoraria: Amgen, Takeda, Janssen-Cilag, Bristol Myers Squibb, Beigene

Consulting or Advisory Role: Amgen, Janssen-Cilag, Takeda, Bristol Myers Squibb, Beigene

Michaela Liedtke

Honoraria: Pfizer

Consulting or Advisory Role: GlaxoSmithKline, Sanofi, Oncopeptides, Kite/Gilead, Alnylam, Karyopharm Therapeutics, Bristol Myers Squibb, Kura Oncology, Takeda, Janssen, Natera, Adaptive Biotechnologies

Ronald Witteles

Consulting or Advisory Role: Alnylam, Ionis Pharmaceuticals, Intelia, Janssen, Bridgebio, Novo Nordisk

Research Funding: Janssen, Alnylam, Pfizer, Bridgebio, Ionis Pharmaceuticals

Travel, Accommodations, Expenses: Novo Nordisk, Pfizer

Vaishali Sanchorawala

Honoraria: Pfizer, Janssen

Consulting or Advisory Role: Proclara, Caelum Biosciences, Janssen Research & Development, AbbVie, Regeneron, Protego Biopharma

Research Funding: Takeda (Inst), Celgene (Inst), Prothena (Inst), Janssen (Inst), Oncopeptides (Inst), Caelum Biosciences (Inst), Karyopharm Therapeutics (Inst)

Heather Landau

Consulting or Advisory Role: Celgene, Takeda, Caelum Biosciences, Juno Therapeutics, Karyopharm Therapeutics, Janssen, HCA Healthcare, Spectrum Pharmaceuticals, Clinical Care Options, Amgen

Research Funding: Takeda

Erica Petrlik

Employment: Bristol Myers Squibb/Celgene

Stock and Other Ownership Interests: Bristol Myers Squibb/Celgene

Suzanne Lentzsch

This author is an Associate Editor for Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.

Leadership: Caelum Biosciences

Stock and Other Ownership Interests: Caelum Biosciences

Consulting or Advisory Role: Janssen, Caelum Biosciences, Takeda, Sanofi, Sorrento Therapeutics, Celularity, GlaxoSmithKline, AbbVie/Genentech, Natara, Pfizer, Oncopeptides

Speakers' Bureau: PeerView, Clinical Care Options

Research Funding: Sanofi

Patents, Royalties, Other Intellectual Property: Patent 11-1F4 mAb for use in AL Amyloidosis

Joan Bladé

Honoraria: Janssen, Celgene, Amgen, Takeda, Oncopeptides

Maria Teresa Cibeira

Honoraria: Janssen, Amgen, Akcea Therapeutics

Consulting or Advisory Role: Janssen, Akcea Therapeutics, Sanofi/Aventis

Ashutosh Wechalekar

Honoraria: Janssen-Cilag, Takeda, Celgene

Consulting or Advisory Role: Caelum Biosciences, GlaxoSmithKline, Alexion Pharmaceuticals, Attralus

Travel, Accommodations, Expenses: Takeda, Janssen

Morie A. Gertz

Honoraria: Celgene, Med Learning Group, Research to Practice, Prothena, Apellis Pharmaceuticals, Amgen, AbbVie, Akcea Therapeutics, Sanofi, Telix Pharmaceuticals, Janssen Oncology, Juno/Celgene, Alnylam

Consulting or Advisory Role: Prothena, Bristol Myers Squibb/Sanofi

Travel, Accommodations, Expenses: Prothena, Celgene, Novartis

No other potential conflicts of interest were reported.